publication date: Oct. 2, 2020
Issue 37 - Oct. 2, 2020
  • Sexual harassment reporting structures in oncology are broken, The Cancer Letter survey finds

    Women in oncology who face gender bias know what not to do: seek help from their institutions.

    survey by The Cancer Letter found that women in academic oncology who have encountered gender bias at work overwhelmingly accept the notion that their institutions will fail them, and those who do lodge complaints are, with no exception, disappointed.

  • In their own words: Responses to The Cancer Letter survey on gender bias

    These harrowing responses to The Cancer Letter’s survey on gender bias are best represented with no interpretation or analysis.

  • Conversation with The Cancer Letter

    Pamela Kunz: “In any other industry, if someone had behavior like that, they would be fired.”

    Pamela Kunz said she left Stanford School of Medicine because of years of gender-related microaggressions and verbal abuse she experienced there.

  • Conversation with The Cancer Letter

    Leonidas Platanias: These incidents are “really shocking and disturbing”

    Robert H. Lurie Comprehensive Cancer Center Director Leonidas Platanias said gender bias in oncology “is totally unacceptable at all levels. I also think it negatively impacts cancer research. These situations can affect how teams function and, ultimately, have a negative impact in research.”

  • In Brief

    • C. Kent Osborne steps down as director of Dan L Duncan Comprehensive Cancer Center
    • Ruben Mesa named executive director of the Mays Cancer Center
    • Stephen Gruber named head of City of Hope’s Center for Precision Medicine
    • Deirdre Cohen named director of Mount Sinai’s Gastrointestinal Oncology Program
    • James B. Yu named associate chief medical officer for radiation oncology at Smilow
    • Yale awarded SPORE for head and neck cancer research
    • VICC receives “exceptional” score with renewal as an NCI-designated Comprehensive Cancer Center
    • AACR convenes conference on health disparities
    • Melanoma researchers at UCLA receive $13M grant from NIH
    • Ohio State receives $10M NCI grant to study impact of COVID-19 in first responders
    • Ohio State receives $9.1M NCI Grant renewal to support cancer retrovirus research
    • Cancer genomic screening program LC-SCRUM-Asia adopts latest Thermo Fisher Scientific NGS solutions
    • ACS CAN: Executive order on pre-existing condition protections unlikely to help cancer patients and survivors
  • Funding Opportunities

    Lymphoma Research Foundation announces $10M initiative for follicular lymphoma clinical research

    The Lymphoma Research Foundation has announced the establishment of the Jaime Peykoff Follicular Lymphoma Initiative, named for follicular lymphoma survivor and wife of Andrew Peykoff II, owner of Niagara Bottling.

  • TCCL Logo

  • Trials & Tribulations

    The cancer detection rate—a public health approach to early detection

    Back in the 1960s, the American Cancer Society first began promoting the Pap smear as an effective means of cervical cancer screening. A decade later, early detection of breast cancer through mammography became mainstream.

  • Clinical Roundup

    • Corticosteroids improve survival in critically ill COVID-19 patients
    • Phase III trial shows Opdivo significantly improves DFS as adjuvant therapy for muscle-invasive urothelial carcinoma
    • Yale study reinforces benefit of using targeted therapy for early-stage NSCLC
  • Drugs & Targets

    • Innova Therapeutics receives Rare Pediatric Disease Designation from FDA for IVT-8086 for Osteosarcoma
    • Celyad Oncology collaborates with MSD to evaluate CYAD-101 with Keytruda in microsatellite stable mCRC
    • University of Illinois scientists enter licensing deal with Bayer, Systems Oncology
    • Elevation Oncology and US Oncology Research collaborate to expand genomic testing of solid tumors
  • NCI Trials

    NCI Trials for Oct. 2020

    The National Cancer Institute approved the following clinical research studies last month. 

Copyright (c) 2020 The Cancer Letter Inc.